F2G Ltd, a UK- and Austria-based developer of novel therapies for life-threatening systemic fungal infections, has secured $60.8 million in financing. The investors included Cowen Healthcare Investments, Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences. In addition to the funding, Naveed Siddiqi, a partner at Novo Ventures, joins the F2G board, replacing Martin Edwards who is retiring. F2G Ltd is a portfolio company of Novo Ventures.
Source: Press Release